Montco firm working to prevent HIV is sold: A Calif. biotech will spend $30 million for Biosyn Inc, which has a gel to fight AIDS in late-stage clinical trials
Article Abstract:
Cellegy Pharmaceuticals Inc. a California biotechnology companies plans to buy privately held Biosyn Inc, of Huntingdon Valley, in a deal valued at $30 million to acquire a contraceptive gel intended to prevent the transmission of HIV. Cellegy's officials state that Biosyn's product could be on the market by the end of 2007 and it would have a major importance in the developing world to stop the spread of AIDS.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Good will: Drugmakers' gifts of cash and supplies have been miraculous, say relief workers
Article Abstract:
The outpouring of cash and supplies by corporations and pharmaceutical and health-care products companies after the tsunami disaster has surpassed donations to victims in any previous natural disaster. Health-care companies, which have announced donations totaling at least $72 million, are trying to improve their image after paltry earnings growth and doubts about drug safety.
Publication Name: Philadelphia Inquirer (PA)
Subject: Business, regional
ISSN: 0885-6613
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Monsanto ordered to pay Pa. damages; a jury awarded the state $90 million for PCB contamination of offices. The firm plans to appeal
- Abstracts: Local firm connects to the heartland via satellite TV. Signs of times: Firm has mixed new technology, old world technique
- Abstracts: Business directory feud goes to court. Striking oil-in a landfill: N.J. man has a plan to turn old tires into fuel, but can it be profitable?
- Abstracts: Magellan is to cut therapy payments. Nomadic 'travel nurses' fill shortages at hospitals. Regional effort aims to reduce drug errors
- Abstracts: Profit-driven hospitals knock on region's door. Merck shares fall after critical Vioxx study